Serum visfatin and vaspin levels in prepubertal children: Effect of obesity and weight loss after behavior modifications on their secretion and relationship with glucose metabolism

International Journal of Obesity

Volumn 35, Issue 10, 2011, Pages 1355-1362

  Martos Moreno, G A ^a,b   Kratzsch, J ^c   Korner A ^d   Barrios, V ^a,b   Hawkins, F ^e   Kiess, W ^d   Argente, J ^a,b  

^a HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESÚS   (Spain)

^b Instituto de Salud Carlos III   (Spain)

^c Institute of Laboratory Medicine   (Spain)

^d UNIVERSITY OF LEIPZIG   (Germany)

^e HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

childhood obesity; HOMA; insulin; NAMPT; vaspin; visfatin

Indexed keywords

ADIPONECTIN; INSULIN; INTERLEUKIN 6; LEPTIN; LEPTIN RECEPTOR; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; RESISTIN; TUMOR NECROSIS FACTOR ALPHA; VASPIN;

ARTICLE; BEHAVIOR MODIFICATION; BODY COMPOSITION; BODY MASS; CAUCASIAN; CHILD; CONSERVATIVE TREATMENT; CONTROLLED STUDY; FEMALE; GLUCOSE METABOLISM; HUMAN; MAJOR CLINICAL STUDY; MALE; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PREPUBERTY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCHOOL CHILD; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

AREA UNDER CURVE; BODY MASS INDEX; CHILD; CHILD, PRESCHOOL; CYTOKINES; FEMALE; GLUCOSE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN RESISTANCE; MALE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OBESITY; PUBERTY; SERPINS; WEIGHT LOSS;

EID: 80053970864     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2010.280     Document Type: Article

References (37)

1. Körner A, Kratzsch J, Kiess W. Adipocytokines: leptin-the classical, resistin-the controversical, adiponectin-the promising, and more to come. Best Pract Res Clin Endocrinol Metab 2005; 19: 525-546.
2. Tilg H, Moschen AR. Inflammatory mechanisms in the regulation of insulin resistance. Mol Med 2008; 14: 222-231. (Pubitemid 351481853)
3. Pajvani UB, Hawkins M, Combs TP, Rajala MW, Doebber T, Berger JP et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem 2004; 279: 12152-12162. (Pubitemid 38445780)
4. Revollo JR, Körner A, Mills KF, Satoh A, Wang T, Garten A et al. Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab 2007; 6: 363-375. (Pubitemid 350011996)
5. Saddi-Rosa P, Oliveira CS, Giuffrida FM, Reis AF. Visfatin, glucose metabolism and vascular disease: a review of evidence. Diabetol Metab Syndr 2010; 2: 21.
6. Li Q, Chen R, Moriya J, Yamakawa J, Sumino H, Kanda T et al. A novel adipocytokine, visceral adipose tissue-derived serine protease inhibitor (vaspin), and obesity. J Int Med Res 2008; 36: 625-629.
7. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005; 307: 426-430. (Pubitemid 40139988)
8. Haider DG, Schindler K, Schaller G, Prager G, Wolzt M, Ludvik B. Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. J Clin Endocrinol Metab 2006; 91: 1578-1581.
9. Berndt J, Klöting N, Kralisch S, Kovacs P, Fasshauer M, Schön MR et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 2005; 54: 2911-2916. (Pubitemid 41401086)
10. Klöting N, Berndt J, Kralisch S, Kovacs P, Fasshauer M, Schön MR et al. Vaspin gene expression in human adipose tissue: association with obesity and type 2 diabetes. Biochem Biophys Res Com 2006; 339: 430-436. (Pubitemid 41697566)
11. Jeong E, Youn BS, Kim DW, Kim EH, Park JW, Namkoong C et al. Circadian rhythm of serum vaspin in healthy male volunteers: relation to meals. J Clin Endocrinol Metab 2010; 95: 1869-1875.
12. von Loeffelholz C, Möhlig M, Arafat AM, Isken F, Spranger J, Mai K et al. Circulating vaspin is unrelated to insulin sensitivity in a cohort of nondiabetic humans. Eur J Endocrinol 2010; 162: 507-513.
13. Ye Y, Hou XH, Pan XP, Lu JX, Jia WP. Serum vaspin level in relation to postprandial plasma glucose concentration in subjects with diabetes. Chin Med J 2009; 122: 2530-2533.
14. Chang HM, Lee HJ, Park HS, Isken F, Spranger J, Mai K et al. Effects of weight reduction on serum vaspin concentrations in obese subjects: modification by insulin resistance. Obesity 2010; 18: 2105-2110.
15. Youn BS, Klöting N, Kratzsch J, Lee N, Park JW, Song ES et al. Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes 2008; 57: 372-377.
16. Haider DG, Holzer G, Schaller G, Weghuber D, Widhalm K, Wagner O et al. The adipokine visfatin is markedly elevated in obese children. J Pediatr Gastroenterol Nutr 2006; 43: 548-549. (Pubitemid 44569022)
17. Araki S, Dobashi K, Kubo K, Kawagoe R, Yamamoto Y, Kawada Y et al. Plasma visfatin concentration as a surrogate marker for visceral fat accumulation in obese children. Obesity (Silver Spring) 2008; 16: 384-388. (Pubitemid 351271920)
18. Kolsgaard ML, Wangensteen T, Brunborg C, Joner G, Holven KB, Halvorsen B et al. Elevated visfatin levels in overweight and obese children and adolescents with metabolic syndrome. Scand J Clin Lab Invest 2009; 69: 858-864.
19. Suleymanoglu S, Tascilar E, Pirgon O, Tapan S, Meral C, Abaci A. Vaspin and its correlation with insulin sensitivity indices in obese children. Diabetes Res Clin Pract 2009; 84: 325-328.
20. Lee MK, Jekal Y, Im JA, Kim E, Lee SH, Park JH et al. Reduced serum vaspin concentrations in obese children following shortterm intensive lifestyle modification. Clin Chim Acta 2010; 411: 381-385.
21. Sobradillo B, Aguirre A, Aresti U, Bilbao A, Fernández-Ramos C, Lizarraga A et al. Curvas y tablas de crecimiento (estudio longitudinal y transversal). In: Fundación F Orbegozo (ed). Patrones de crecimiento y desarrollo en España. Atlas de gráficas y tablas. Ergón: Madrid, 2004.
22. Kelly TL, Specker BL, Binkley T, Zemel BS, Leonard MB, Kalkwarf HJ et al. Pediatric BMD reference database for US white children. Bone 2005; 36: S5-102.
23. Körner A, Garten A, Blüher M, Tauscher R, Kratzsch J, Kiess W. Molecular characteristics of serum visfatin and differential detection by immunoassays. J Clin Endocrinol Metab 2007; 92: 4783-4791. (Pubitemid 350223461)
24. Martos-Moreno GA, Barrios V, Mart́nez G, Hawkins F, Argente J. Effect of weight loss on high-molecular weight adiponectin in obese children. Obesity (Silver Spring) 2010; 18: 2288-2294.
25. Haffner SM, Stern MP, Hazuda HP, Pugh JA, Patterson JK. Hyperinsulinemia in a population at high risk for non-insulindependent diabetes mellitus. N Engl J Med 1986; 315: 220-224. (Pubitemid 16097123)
26. Manco M, Fernandez-Real JM, Equitani F, Vendrell J, ValeraMoraME, Nanni G et al. Effect of massive weight loss on inflammatory adipocytokines and the innate immune system in morbidly obese women. J Clin Endocrinol Metab 2007; 92: 483-490.
27. Krzyzanowska K, Mittermayer F, Krugluger W, Kopp HP, Schernthaner G. Increase in visfatin after weight loss induced by gastroplastic surgery. Obesity (Silver Spring) 2006; 14: 1886-1889. (Pubitemid 46121917)
28. Haider DG, Schaller G, Kapiotis S, Maier C, Luger A, Wolzt M. The release of the adipocytokine visfatin is regulated by glucose and insulin. Diabetologia 2006; 49: 1909-1914. (Pubitemid 44025046)
29. Unlütürk U, Harmanci A, Yildiz BO, Bayraktar M. Dynamics of Nampt/visfatin and high molecular weight adiponectin in response to oral glucose load in obese and lean women. Clin Endocrinol (Oxf) 2010; 72: 469-474.
30. Chang YC, Chang TJ, Lee WJ, Chuang LM. The relationship of visfatin/pre-B-cell colony-enhancing factor/nicotinamide phosphoribosyltransferase in adipose tissue with inflammation, insulin resistance, and plasma lipids. Metabolism 2010; 59: 93-99.
31. Fain JN. Release of interleukins and other inflammatory cytokines by human adipose tissue is enhanced in obesity and primarily due to the nonfat cells. Vitam Horm 2006; 74: 443-477.
32. Curat CA, Wegner V, Sengenès C, Miranville A, Tonus C, Busse R et al. Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia 2006; 49: 744-747. (Pubitemid 43357549)
33. Dedoussis GV, Kapiri A, Samara A, Dimitriadis D, Lambert D, Pfister M et al. Visfatin: the link between inflammation and childhood obesity. Diabetes Care 2009; 32: e71.
34. Aller R, de Luis DA, Izaola O, Sagrado MG, Conde R, Velasco MC et al. Influence of visfatin on histopathological changes of nonalcoholic fatty liver disease. Dig Dis Sci 2009; 54: 1772-1777.
35. Jia SH, Li Y, Parodo J, Kapus A, Fan L, Rotstein OD et al. Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. J Clin Invest 2004; 113: 1318-1327. (Pubitemid 39069931)
36. Cho JK, Han TK, Kang HS. Combined effects of body mass index and cardio/respiratory fitness on serum vaspin concentrations in Korean young men. Eur J Appl Physiol 2010; 108: 347-353.
37. González CR, Caminos JE, Vázquez MJ, Garcés MF, Cepeda LA, Angel A et al. Regulation of visceral adipose tissue-derived serine protease inhibitor by nutritional status, metformin, gender and pituitary factors in rat white adipose tissue. J Physiol 2009; 587: 3741-3750.